Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) Products under Development by Stage of Development | 7 | 1 |
| Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) Products under Development by Therapy Area | 8 | 1 |
| Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) Products under Development by Indication | 9 | 1 |
| Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) Products under Development by Companies | 12 | 2 |
| Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) Products under Development by Universities/Institutes | 14 | 2 |
| Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) Therapeutics Assessment | 16 | 4 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 1 |
| Assessment by Route of Administration | 18 | 1 |
| Assessment by Molecule Type | 19 | 1 |
| Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) Companies Involved in Therapeutics Development | 20 | 5 |
| Array BioPharma Inc. | 20 | 1 |
| Incyte Corporation | 21 | 1 |
| Inflection Biosciences Limited | 22 | 1 |
| Jasco Pharmaceuticals, LLC. | 23 | 1 |
| Novartis AG | 24 | 1 |
| Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) Drug Profiles | 25 | 8 |
| AR-460770 Drug Profile | 25 | 1 |
| Drugs to Inhibit PIM-1 Kinase for Respiratory and Immunological Diseases Drug Profile | 26 | 1 |
| IBL-100 Drug Profile | 27 | 1 |
| INCB-53914 Drug Profile | 28 | 1 |
| LGB-321 Drug Profile | 29 | 1 |
| PIM-447 Drug Profile | 30 | 1 |
| Small Molecules to Inhibit Pim Kinase for Oncology Drug Profile | 31 | 1 |
| Small Molecules to Inhibit Pim-1 for Prostate Cancer Drug Profile | 32 | 1 |
| Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) Dormant Projects | 33 | 3 |
| Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) Discontinued Products | 36 | 1 |
| Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) Featured News &Press Releases | 37 | 1 |
| Apr 01, 2013: Jasco Pharma To Present Data On PIM Inhibitor Program At AACR Annual Meeting 2013 | 37 | 1 |
| Mar 31, 2011: Jasco Pharma To Present Data On Preclinical PIM Inhibitor Program At AACR Annual Meeting | 37 | 1 |
| Appendix | 38 | 2 |
| Methodology | 38 | 1 |
| Coverage | 38 | 1 |
| Secondary Research | 38 | 1 |
| Primary Research | 38 | 1 |
| Expert Panel Validation | 38 | 1 |
| Contact Us | 38 | 1 |
| Disclaimer | 39 | 1 |